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Abstract 
Background: Information on the clinical, epidemiological and molecular characterization of human metapneu-
movirus in critically ill adult patients with severe community-acquired pneumonia (CAP) and the role of biomarkers 
identifying bacterial coinfection is scarce.
Methods: This is a retrospective epidemiological study of adult patients with hMPV severe CAP admitted to ICU dur-
ing a ten-year period with admission PSI score ≥ 3.
Results: The 92.8% of the 28 patients with severe CAP due to human metapneumovirus were detected during the 
first half of the year. Median age was 62 years and 60.7% were male. The genotyping of isolated human metapneumo-
virus showed group B predominance (60.7%). All patients had acute respiratory failure. Median APACHE II and SOFA 
score were 13 and 6.55, respectively. The 25% were coinfected with Streptococcus pneumoniae. 60.7% of the patients 
had shock at admission and 50% underwent mechanical ventilation. Seven patients developed ARDS, three of them 
younger than 60 years and without comorbidities. Mortality in ICU was 14.3%. Among survivors, ICU and hospital stay 
were 6.5 and 14 days, respectively. Plasma levels of procalcitonin were higher in patients with bacterial coinfection 
(18.2 vs 0.54; p < 0.05). The levels of C-reactive protein, however, were similar.
Conclusion: Human metapneumovirus was associated with severe CAP requiring ICU admission among elderly 
patients or patients with comorbidities, but also in healthy young subjects. These patients often underwent mechani-
cal ventilation with elevated health resource consumption. While one out of four patients showed pneumococcal 
coinfection, plasma procalcitonin helped to implement antimicrobial stewardship.
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Background
Human metapneumovirus (hMPV) is a worldwide dis-
tributed enveloped virus with a RNA genome closely 
related to respiratory syncytial virus. hMPV belongs to 
the Paramyxoviridae family, in the genus Metapneu-
movirus, first identified in the Netherlands in 2001 [1]. 
Based on genetic and antigenic variability, hMPV strains 
have been classified in two groups or lineages (A and 
B) and four sublineages (A1, A2, B1 and B2) [1–3]. The 
virus has been reported as a common respiratory patho-
gen in childhood, associated mainly with upper but also 
with lower respiratory tract infections [2, 4]. During the 
annual epidemics, hMPV has been associated with a sig-
nificant number of hospital admissions in young children 
[4–7].
Respiratory tract infections caused by hMPV during 
adulthood are less prevalent and less serious than those 
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in childhood. However, the presence of hMPV has been 
detected in 2–4% of adult patients admitted due to a 
community-acquired pneumonia (CAP) [8, 9] and has 
been associated with asthma and chronic obstructive 
pulmonary disease exacerbation [10–12]. The same as 
with other common respiratory viruses, hMPV is usu-
ally associated with non-severe pneumonia, whereas 
risk factors like immunosuppression, specific comorbidi-
ties—chronic lung disease, heart disease, blood disor-
ders— elderly and living in long-term care facilities are 
associated with a higher risk of severe viral pneumonia 
[13, 14]. Nevertheless, recent studies suggest that hMPV 
infection is an underappreciated cause of critical illness, 
also in previously healthy patients [15–18].
Severe community-acquired pneumonia (SCAP) is a 
known infectious complication of respiratory viruses 
including hMPV. In these cases, clinical presentation, 
evolution and treatment differ depending on the patho-
gens involved, hMPV alone or hMPV coinfected with a 
bacteria. Some biomarkers have been studied as diag-
nostic markers to discriminate between viral or bacterial 
pneumonias and help physicians to decide not to start or 
when to withdraw the antibiotic therapy [19, 20].
The main objective of this study was to describe the 
clinical and epidemiological characteristics of adults 
with severe pneumonia caused by hMPV who required 
intensive care unit (ICU) admission, over a long period 
of time. Secondary objectives were to characterize the 
epidemiological and molecular viral diversity and to 
compare the value of C-reactive protein (CRP) and proc-
alcitonin in identifying bacterial coinfections.
Methods
This is a ten-year, retrospective epidemiological study 
with inclusion of patients with CAP due to hMPV admit-
ted in a 48-bed ICU in the North of Spain. In 2017, this 
ICU assisted a referral population of 545,227 inhabitants 
older than 14 years.
All patients older than 14  years from July 2007 to 
June 2017 admitted in the ICU by CAP with admis-
sion PSI score ≥ 3 were considered eligible. During the 
first 2  years of the study, samples to detect respiratory 
viruses were obtained occasionally in patients with CAP. 
However, it turned the standard of care in the ICU after 
2009 influenza pandemic. To be included, cases meet 
two of the following three criteria upon admission: (a) 
severe acute respiratory failure (paO2/FiO2 < 250), (b) 
multilobar radiological involvement or (c) systolic arte-
rial pressure < 90 mmHg. Acute respiratory distress syn-
drome (ARDS) was diagnosed as an acute diffuse lung 
injury with increased vascular permeability, bilateral 
radiographic opacities and hypoxemia not fully explained 
by cardiac failure or fluid overload following the Berlin 
criteria [21]. Exclusion criteria: subjects with nosocomial 
pneumonia or admitted due to non-respiratory infec-
tion (non-severe coincidental infection) and patients 
with pneumonia during the preceding 2 months (persis-
tence of viral RNA in respiratory samples). Patients were 
recruited from the computerized records of the Microbi-
ology department, and the medical records were revised 
by two clinical investigators (IT, LV). The recorded clini-
cal variables were socio-demographic (age and sex), 
comorbidities, the Charlson comorbidity score and 
clinical symptoms at admission [22]. Radiological and 
analytic findings at admission and during the evolution, 
coinfections, antibiotic therapy, the presence of shock 
or need of mechanical ventilation, ICU and hospital stay 
were also recorded.
The detection of hMPV in respiratory samples was 
made by reverse transcription polymerase chain reac-
tion (RT-PCR), in house monoplex until July 2010 [5], 
real-time commercial multiplex (Luminex xTAG Res-
piratory viral panel [USA]) until July 2013 and Seegene 
Anyplex™  II RV16/Allplex™ Respiratory Panel [Republic 
of Korea] since then. The extraction of nucleic acids was 
made using an automatic BioRobot1 M48 extractor (Qia-
gen GmbH, Hilden, Germany) until July 2009 and the 
 NucliSENS® Easy-Mag platform (bio-Mèrieux SA, Marcy 
l’Etoile, France) from that date. The genotyping of hMPV 
was performed with a RT-PCR followed by sequenc-
ing [23]. Blood cultures, Streptococcus pneumoniae and 
Legionella pneumophila antigenuria (Alere BinaxNOW, 
Scarborough, ME, USA), and pharyngeal exudates with 
viral transport media to evaluate respiratory viruses were 
assessed in all the patients included in the study. Coinfec-
tion was considered when hMPV was isolated with other 
viral or bacterial pathogens at the same time.
Discrete variables were expressed as counts (percent-
age) and continuous variables as medians and 25–75% 
interquartile ranges (IQRs). Differences in continuous 
variables were analyzed by the Mann–Whitney U test or 
the Kruskall–Wallis test when appropriate. Qualitative 
variables were analyzed by the Chi-square test with Yate’s 
correction when necessary. The threshold for clinical sig-
nificance was p < 0.05. Data analysis was performed using 
SPSS for Windows 21.0.0 (SPSS, Chicago, IL, USA). The 
obtained clinical samples and the medical intervention of 
the patients were ordered by the clinician attending each 
patient. The study was approved by the ethics commit-
tee for clinical research of the health area of Gipuzkoa 
(Spain). Informed consent was waived due to the retro-
spective nature of the study.
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Results
During the study period, 1942 respiratory samples were 
sent from the ICU to the Microbiology Service to study 
viral etiology, hMPV being identified in 33 patients 
(1.7%). Studied samples were mainly pharyngeal exudates 
(77.3%), but also tracheal aspirates (7.5%), bronchoaspi-
rates (5.8%), bronchoalveolar lavages (5.6%) and sputum 
(4.2%), where bacterial culture was also performed. Five 
patients with hMPV were excluded because admission 
causes were other than respiratory infection. Cases were 
detected every year except in 2008 (n = 0–5). The highest 
prevalence was in 2015 and 2017 (Fig. 1). Twenty-six of 
the 28 patients with respiratory infection due to hMPV 
(92.9%) were detected during the first half of the year 
and 16 (57.1%) in March–April. HMPV circulated every 
year later than influenza virus, being the epidemic peak 
of both infections separated by a period of 1–2 months. 
In fact, the 75% of cases (21/28) of hMPV infections in 
patients admitted to ICU occurred out of the influenza 
epidemic period (Table 1).
Genotyping of hMPV was performed in 27 cases, being 
ten cases of hMPV group A (39.3%) and 17 of hMPV 
group B (60.7%). The viral strains belonged to subline-
ages A2 (n = 10; 39.3%), B1 (n = 11; 39.3%) and B2 (n = 6; 
21.4%). Group A strains predominated until 2011 (72.7%), 
while later, the most frequent was genotype B (79%). 
After excluding seven patients with bacterial coinfection, 
there were not significant differences in the genotype of 
hMPV between six patients who developed ARDS (60% 
genotype B) and 15 who did not (67% genotype B).
At ICU admission, all patients had acute respiratory 
failure and received empiric antibiotic therapy. Median 
APACHE II score was 13 [IQR 11.2–20], and median 
SAPS III and SOFA scores were 58.5 [IQR 47.2–70.7] 
and 6.5 [IQR 3.5–9.5], respectively. Median age of the 
included patients was 62 years [25–75% IQR 49.7–75.7], 
and 60.7% of them were under 65 years old (9 with less 
than two comorbidities). The 60.7% (n = 17) of the 
patients were male. Main symptoms at admission were 
cough (89.3%), dyspnea (71.4%), fever (67.9%) and puru-
lent respiratory secretions (67.8%). Nineteen patients 
(67.9%) had major comorbidities such as immune com-
promise (n = 7), asthma (n = 3) or chronic respiratory 
disease (n = 3) (Table  2). Seven patients (none died) 
had coinfection with Streptococcus pneumoniae. Three 
episodes were coinfected with viral pathogens: human 
parainfluenza virus type 3 (hPIV3), human rhinovirus 
and cytomegalovirus (last one in an immunosuppressed 
patient).
Predominant radiologic pattern in patients with hMPV 
infection and without coinfection was the interstitial 
alveolar pattern (47.6%), while in the patients with Strep-
tococcus pneumoniae coinfection, the alveolar pattern 
was predominant (85.7%). Eight patients had pleural effu-
sion at admission, and two more developed it during the 
ICU stay. Pleural effusion was bilateral in four patients 
and massive (> 2 L) in three cases.
Seventeen (60.7%) patients had shock at admission, 
fourteen (50%) underwent invasive mechanical venti-
lation (median 5.5 days [IQR 5–14.2]) due to acute res-
piratory failure and four were tracheostomized due to 
prolonged mechanical ventilation. Severe complications 
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Fig. 1 Cases of severe community-acquired pneumonia associated 
with human metapneumovirus infection, hospitalized in the Intensive 
Care Unit of a large regional hospital (San Sebastián, North of Spain)
Table 1 Annual epidemic peaks of influenza virus and human 
metapneumovirus infections, and  temporal distribution 
of  isolates in  patients with  severe community-acquired 
pneumonia due to  human metapneumovirus infection 
(Gipuzkoa, Spain, 2008–2017)
hMPV human metapneumovirus, SCAP severe community-acquired pneumonia
Year Flu epidemic peak hMPV 
epidemic 
peak
SCAP hMPV
2008 January (2nd week) March None
2009 December (2008)
(50th week)
January April (n = 1)
July (n = 1)
2010 October (2009) Pandemia
(42th week)
March March (n = 3)
2011 January (1st week) March March (n = 2)
April (n = 1)
2012 February (7th week) March June (n = 2)
2013 February (7th week) March May (n = 1)
July (n = 1)
2014 January (3rd week) March January 2014 (n = 1)
April 2014 (n = 1)
2015 February (5th week) March January (n = 1)
March (n = 1)
April (n = 2)
May (n = 1)
2016 January (4th week) March March (n = 3)
2017 January (3rd week) March January (n = 2)
February (n = 1)
March (n = 2)
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were frequent, highlighting acute renal failure in 12 
patients (42.8%), of which two required renal replace-
ment therapy; cardiac failure or cardiogenic shock in 
eight patients (28.5%); and ARDS in seven cases (25%) 
(two of them in patients with bacterial coinfection) 
(Table  2). Three patients who developed ARDS were 
younger than 60 years (38, 47 and 54 years, respectively) 
without major comorbidities or bacterial coinfection. All 
of them underwent invasive mechanical ventilation due 
to acute respiratory failure (one had coinfection with 
hPIV3). The main clinical and epidemiological charac-
teristics of the patients are summarized in the Supple-
mentary material (Additional file 1: Table S1, Additional 
file 2: Table S2). The majority of the patients (83.3%) had 
lymphocytopenia (< 1000/mL) at admission (Table  2). 
Four patients (average age 68.5  years), three of them 
immunocompromised, died during the ICU stay due to 
complications of respiratory failure. Among survivors, 
ICU and hospital median stay were 6.5 [IQR 5–11.7] and 
14 [IQR 10–23.3] days, respectively. Survival rate after 
hospital discharge at 3 and 6 months was 97.1% (n = 23) 
and 87.5% (n = 21), respectively.
The median CRP and procalcitonin plasma levels at 
ICU admission in the 28 hMPV-infected patients with 
CAP were 125 [44.6–305.9] mg/L and 1.3 [0.2–9.3] ng/
mL, respectively. The values of CRP were similar between 
patients with bacterial coinfection and those without 
(median 231.4 [IQR 84.0–407.5] vs 110.2 [38–281.7] 
mg/L; p = 0.29). In contrast, the plasma levels of procal-
citonin were higher in the patients with bacterial coinfec-
tion than in those without (median, 18.2 [IQR 8.4–57.6] vs 
0.54 [0.1–1.9] ng/mL, p < 0.005). All patients with bacterial 
coinfection had procalcitonin > 1 ng/mL at ICU admission.
Discussion
Our study gives new insights on the molecular epi-
demiology of hMPV pneumonia admitted to the ICU 
over 10 years. HMPV was consistently detected in CAP 
admitted to the ICU, with an annual incidence rang-
ing 0.5–1 case/100,000 inhabitants older than 14  years 
per year. Molecular characterization of hMPV revealed 
group dominance of subgroup B. HMPV infection pre-
sented seasonal distribution, with 2/3 of cases detected in 
late winter-early spring each year. The 32% of the stud-
ied patients were younger than 65 years without comor-
bidities. HMPV CAP often presented as acute respiratory 
failure with bilateral opacities and half of ICU subjects 
underwent mechanical ventilation. Lymphocytopenia 
and pleural effusion were common at admission. Plasma 
procalcitonin was a sensitive tool to identify coinfection 
with bacteria (25%), which contributes to antimicrobial 
stewardship. These findings suggest the need to imple-
ment hMPV diagnosis tests in subjects with CAP devel-
oping acute respiratory failure.
Two out of three patients of this study had shock at 
admission, half of them underwent mechanical venti-
lation, one out of four developed ARDS and one out of 
seven died during the clinical course, suggesting that 
hMPV is responsible for SCAP in adults. These data are 
concordant to that observed in the only study with a wide 
range of patients with hMPV infection in critically ill 
patients, in which 55% of the patients required mechani-
cal ventilation, 48% developed ARDS and the mortal-
ity was 18% [18]. Moreover, there are sporadic reports 
of 3–6 patients with hMPV infection acquired in the 
community and acute respiratory failure who required 
ICU admission [15–17]. In a large prospective study of 
ICU patients requiring invasive mechanical ventilation, 
hMPV was more frequently detected in patients admitted 
Table 2 Demographic characteristics of  the  study 
population
COPD chronic obstructive pulmonary disease
Total n 
(%)
Bacterial 
coinfection 
(n)
Without 
bacterial 
coinfection 
(n)
Study patients (n) 28 (100) 7 21
Male 17 (60.7) 5 12
Age (years) median [ICR] 62 [50 to 
76]
62 [61 to 83] 62 [48 to 75]
Comorbidities
 COPD 3 (10.7) 1 2
 Asthma 3 (10.7) 0 3
 Heart failure 2 (7.1) 1 1
 Alcoholism 3 (10.7) 0 3
 Immunosuppression 7 (25.0) 2 5
 No comorbidities 11 (39.3) 3 8
Clinical manifestations
 Fever 19 (67.9) 6 13
 Cough 25 (89.3) 6 19
 Purulent secretions 19 (67.9) 5 14
 Dyspnea 20 (71.4) 5 15
Radiologic pattern
 Alveolar 15 (53.6) 6 9
 Interstitial 3 (10.7) 1 2
 Interstitial alveolar 10 (35.7) 0 10
 Bilateral 17 (60.7) 2 15
 Pleural effusion 8 (28.6) 2 6
Complete blood count
 Leukopenia/leukocy-
tosis/mm3 (< 4000 
year > 11,000)
16 (57.1) 4 12
 Thrombocytopenia/
mm3 (< 150,000)
9 (32.1) 4 5
 Lymphopenia/mm3 
(< 1000)
23 (82.1) 6 17
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by severe respiratory infection than in patients with other 
causes, suggesting a causal role of HMPV in the develop-
ment of severe respiratory infection [24].
Most of the patients of this study had major comorbidi-
ties at admission, mainly chronic respiratory failure and 
immunosuppression, being those patients and the elderly 
the most susceptible to develop severe hMPV infections 
[2, 10, 14]. However, 60% of the patients were younger 
than 65 years old and one out of three did not have major 
comorbidities, being similar to CAP related to other eti-
ologies. Interestingly, three patients (10.7%) were young 
adult patients without comorbidities and without bacterial 
coinfection that developed ARDS pointing out a main role 
of hMPV in the etiology of severe respiratory infections 
requiring mechanical ventilation. In the cohort of patients 
of Hasvold et al. [18], 15% of the patients had only minor 
comorbidities and were not immunosuppressed.
One out of four episodes of severe acute respiratory 
infection was coinfected with bacteria, similar to that 
observed in other series [17, 18]. Streptococcus pneu-
moniae, one of the bacterial species most frequently 
involved in post-viral super-infections [25], was the main 
isolated bacterial pathogen. In these episodes, procal-
citonin has been reported to discriminate between viral 
episodes and those with bacterial coinfection [26], in 
contrast with CRP. Some studies have recommended dif-
ferent cutoff points of procalcitonin to discontinue early 
antibiotic therapy in patients with community-acquired 
therapy, being 0.25  ng/mL and, mainly 0.1  ng/mL the 
most recommended [27, 28]. None of the patients with 
documented bacterial coinfection in this study had a pro-
calcitonin level lower than 1 ng/mL which supports the 
early discontinuation of antibiotic therapy in this group 
of patients with low plasma levels of procalcitonin. The 
results of this study, about procalcitonin plasma determi-
nations, could help to develop personalized medicine in 
patients with CAP, helping physicians to early discrimi-
nation between viral or bacterial pneumonia and antimi-
crobial stewardship [29].
Three different genotypes of hMPV were associated 
with severe CAP requiring ICU admission, which sup-
ports that all of them are able to cause severe infections in 
adult patients. The low number of cases of the three differ-
ent hMPV lineages, the presence of coinfections and the 
retrospective nature of the study made impossible to ana-
lyze the clinical pattern and the evolution of the patients 
based on the genotype of the infecting hMPV. However, 
to date, there are no significant differences in the evolu-
tion or clinical manifestation between different genotypes 
of HMPV in adults in the outpatient setting [30].
This study has some limitations and therefore, the 
results should be evaluated cautiously. The hMPV 
infection was diagnosed by oropharyngeal swab sam-
ples more than in low respiratory tract samples, mainly 
in non-intubated patients. The detection of a viral path-
ogen in respiratory samples of a patient with acute res-
piratory infection can be coincident and not related to 
ICU admission. The retrospective design of the study 
can underestimate the actual incidence of hMPV infec-
tion because some patients admitted because of acute 
respiratory infection could not be investigated for viral 
etiology. However, from the 2009 influenza pandem-
ics, nasopharyngeal swab samples with respiratory viral 
detection are routine of care being collected in the 90% 
of patients with SCAP admitted to ICU. Finally, three dif-
ferent molecular techniques were used, with potential 
selection bias due to the differences in sensitivity of these 
techniques.
Conclusion
In conclusion, our study confirms that hMPV, a res-
piratory virus causing bronchiolitis and pneumonia 
in children, was associated with severe CAP requiring 
ICU admission among elderly patients or patients with 
comorbidities, but also in healthy young subjects. These 
patients often underwent mechanical ventilation with 
long ICU and hospital stays, associated with elevated 
health resource consumption. The results of this study 
agree with recent observations [13] suggesting a shift in 
the paradigm of severe pneumonia, recommending that 
viral infection (and specifically hMPV) should be ruled 
out when complicated with acute respiratory failure. 
While one out of four patients showed pneumococcal 
coinfection, plasma procalcitonin levels helped to imple-
ment antimicrobial stewardship.
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